IDiyas

For the Inventor, By the Inventor

Daly City, CA, United States of America

Donald E Bierer

USPTO Granted Patents = 14

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 31(Granted Patents)


Company Filing History:

goldMedal14 out of 22 
 
Shaman Pharmaceuticals, Inc.
 patents
silverMedal2 out of 3,370 
 
University of Michigan
 patents
where one patent can have more than one assignee

Years Active: 1996-1999

Loading Chart...
14 patents (USPTO):Explore Patents
1. 5925647 - Methods for use of cryptolepine analogs with hypoglycemic activity (1999-07-20),
2. 5917052 - Hypoglycemic agent from cryptolepis (1999-06-29),
3. 5811568 - Process for the preparation of mono- and bis(phosphocholine) (1998-09-22),
4. 5753790 - Hypoglycemic agent from cryptolepis (1998-05-19),
5. 5741926 - Aniline derivatives having antihyperglycemic activity (1998-04-21),
6. 5681958 - Cryptolepine analogs with hypoglycemic activity (1997-10-28),
7. 5681829 - Class of phosphocholine derivatives having antifungal activity (1997-10-28),
8. 5668168 - 1,2-dithiin antiinfective agents (1997-09-16),
9. 5648354 - 1,2-dithiins having antifungal activity (1997-07-15),
10. 5629319 - Hypoglycemic agent from cryptolepis (1997-05-13),
11. 5628999 - Hypoglycemic agent from cryptolepis (1997-05-13),
12. 5583235 - Preparation of symmetrical and unsymmetrical (1996-12-10),
13. 5580897 - 1,2-dithiins having antifungal activity (1996-12-03),
14. 5556875 - 1,2-dithiin antiinfective agents (1996-09-17),

Title: The Innovations of Donald E Bierer

Introduction

Donald E Bierer is a notable inventor based in Daly City, California. He holds a total of 14 patents, showcasing his significant contributions to the field of hypoglycemic agents. His work primarily focuses on developing novel compounds that can aid in the treatment of diabetes.

Latest Patents

Bierer’s latest patents include methods for the use of cryptolepine analogs with hypoglycemic activity. These novel cryptolepine analogs are useful as hypoglycemic agents, particularly in the treatment of both insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II). Additionally, he has developed a method for synthesizing these compounds. Another significant patent involves the use of extracts from Cryptolepis sp. or quindoline alkaloids, such as quindoline and cryptolepine, as hypoglycemic agents. These extracts are derived from Cryptolepis sanguinolenta and are effective in treating both types of diabetes.

Career Highlights

Throughout his career, Bierer has worked with various organizations, including Shaman Pharmaceuticals, Inc. and the University of Michigan. His experience in these institutions has contributed to his expertise in the development of hypoglycemic agents.

Collaborations

Bierer has collaborated with notable individuals in his field, including Jeffrey M Dener and Thien V Truong. These partnerships have likely enhanced his research and innovation efforts.

Conclusion

Donald E Bierer’s contributions to the field of diabetes treatment through his innovative patents highlight his role as a significant inventor. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…